Loading…
Venmax Drugs & Pharmaceuticals (BSE 531015)₹14.65+5.40%Pharmaceuticals
Venmax Drugs & Pharmaceuticals is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 54.3 against a peer median of 15.6, and ROCE of 3.0% against a peer median of 4.0%, and latest-quarter sales growth of 1,128.1% against a peer median of −12.9%. By market cap it is #6 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bacil Pharma | 24 | 15.6 | — | — | 0.00 | 0.0 | 0 | 2 | — | — | vs BSE 531015 |
| Lasa Supergenerics | 24 | — | −18.0 | −19.6 | 0.20 | 0.0 | 25 | −34 | −100.3 | — | vs BSE 531015 |
| Welcure Drugs & Pharmaceuticals | 24 | — | −3.0 | −5.5 | 0.00 | 0.0 | 366 | −5 | −100.0 | −1,768.9 | vs BSE 531015 |
| Walpar Nutritions | 24 | 9.5 | 14.9 | 13.9 | 0.89 | 0.0 | 79 | 3 | 7.8 | 6.4 | vs BSE 531015 |
| Ishita Drugs & Industries | 22 | 28.3 | 8.6 | 7.0 | 0.01 | 0.0 | 15 | 1 | −32.8 | −36.7 | vs BSE 531015 |
| Venmax Drugs & Pharmaceuticals | 21 | 54.3 | 3.0 | 2.7 | 0.02 | 0.0 | 8 | 0 | 1,128.1 | −87.0 | — |
| Span Divergent | 20 | — | −30.0 | −41.5 | 0.48 | 0.0 | 17 | −3 | −4.6 | — | vs BSE 531015 |
| Mono Pharmacare | 18 | 52.6 | 5.0 | 1.1 | 1.78 | 0.0 | 166 | 0 | 22.1 | −100.0 | vs BSE 531015 |
| Centuple Global | 18 | 11.6 | 15.0 | 12.7 | 0.29 | 0.0 | 575 | 2 | 1,07,642.3 | −1,040.0 | vs BSE 531015 |
| Colinz Laboratories | 18 | 6.4 | 7.2 | 5.3 | 0.04 | 0.0 | 6 | 1 | −21.2 | 1,753.8 | vs BSE 531015 |
| Zenith Health Care | 17 | — | 0.3 | 0.1 | 0.00 | 0.0 | 10 | 0 | −23.7 | −430.0 | vs BSE 531015 |
| Peer median | 21 | 15.6 | 4.0 | 1.9 | 0.04 | 0.0 | 17 | 0 | −12.9 | −93.5 |
Listed companies closest to Venmax Drugs & Pharmaceuticals in Pharmaceuticals include Bacil Pharma, Lasa Supergenerics, Welcure Drugs & Pharmaceuticals, Walpar Nutritions, Ishita Drugs & Industries, Span Divergent, Mono Pharmacare, Centuple Global.
Bacil Pharma, with a market cap of ₹24.22 Cr.
Venmax Drugs & Pharmaceuticals trades at a P/E of 54.3; the median of its peer set is 15.6. A P/E above or below the median is a description, not a judgement on value.
Venmax Drugs & Pharmaceuticals' return on capital employed is 3.0%, below the peer median of 4.0%.